Edition:
United States

Amarin Corporation PLC (AMRN.OQ)

AMRN.OQ on NASDAQ Stock Exchange Global Market

3.05USD
13 Jul 2018
Change (% chg)

$0.03 (+0.99%)
Prev Close
$3.02
Open
$3.00
Day's High
$3.09
Day's Low
$3.00
Volume
968,016
Avg. Vol
410,470
52-wk High
$4.59
52-wk Low
$2.67

Select another date:

Wed, May 2 2018

BRIEF-Amarin Corporation Reports Q1 GAAP Loss Per Share $0.08

* REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES UPDATE ON OPERATIONS

BRIEF-Amarin estimates net product revenue for Q1 to be about $43 mln

* AMARIN UPDATES FIRST QUARTER REVENUE GUIDANCE, REITERATES FULL YEAR GUIDANCE AND UPDATES ON REDUCE-IT CARDIOVASCULAR OUTCOMES STUDY PROGRESS AND VASCEPA PROMOTION INITIATIVES

BRIEF-Amarin's says 100 pct Mark reached on REDUCE-IT Cardiovascular Outcomes Study for Estimated Onset of Target Primary MACE

* IT CARDIOVASCULAR OUTCOMES STUDY REACHES 100% MARK FOR ESTIMATED ONSET OF TARGET PRIMARY MAJOR ADVERSE CARDIOVASCULAR EVENTS

BRIEF-Amarin Corporation Says ‍Ministry Of Public Health In Lebanon Approved Vascepa

* AMARIN CORPORATION PLC - ‍MINISTRY OF PUBLIC HEALTH IN LEBANON HAS APPROVED VASCEPA​

BRIEF-Amarin Reports Fourth Quarter Loss Of $0.08 Per Share

* AMARIN REPORTS RECORD FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES UPDATE ON OPERATIONS

BRIEF-Amarin Prices Public Offering Of American Depositary Shares

* AMARIN PRICES PUBLIC OFFERING OF AMERICAN DEPOSITARY SHARES

BRIEF-Amarin Announces Proposed Public Offering Of American Depositary Shares

* AMARIN ANNOUNCES PROPOSED PUBLIC OFFERING OF AMERICAN DEPOSITARY SHARES

BRIEF-Amarin Announces Commencement Of Vascepa Clinical Development In Mainland China

* AMARIN ANNOUNCES COMMENCEMENT OF VASCEPA CLINICAL DEVELOPMENT IN MAINLAND CHINA Source text for Eikon: Further company coverage:

Select another date: